

Curriculum Vitae

22 December 2017

PERSONAL DATA

Name: Byoung-Gie Kim, M.D., Ph.D.
Present Title and Affiliation: Professor
Department of Obstetrics and Gynecology
Samsung Medical Center
Sungkyunkwan University School of Medicine
Director
Gynecologic Cancer Center
Samsung Medical Center

EDUCATION:

1984	M.D.	Medical College of Seoul Nat. Univ., Seoul, Korea
1995	Master	Medical College of Seoul Nat. Univ., Seoul, Korea
1998	Ph.D.	Medical College of Seoul Nat. Univ., Seoul, Korea

POSTGRADUATE TRAINING:

1987-88	Internship	Seoul Nat. Univ. Hosp., Seoul, Korea
1988-92	Residency	Dept. of Ob/Gyn. Seoul Nat. Univ. Hosp.
1992-93	Postdoc Fellow	Division of Gynecologic Oncology Department of Ob/Gyn. Seoul Nat. Univ. Hosp.
1998-99	Guest Researcher	Lab. of Cell Regulation and Transformation Section Division of Basic Sciences, NCI, Bethesda, MA, USA

SPECIALTY BOARDS:

1984	Korean Board of Medicine (Cert. No. 26911)
1992	Korean Board of Obstetrics & Gynecology (Certi. No. 2694)

SOCIETY MEMBERSHIP:

1984	Korean Medical Association
1988	Korean Society of Gynecologic Endoscopy
1992	Korean Society of Ob/Gyn.
1992	Korean Cancer Research Association

1992	Korean Cancer Society
1992	Korean Society of Gynecologic Oncology (KSGO)
1995	Korean Society of Molecular Biology
1995	International Gynecologic Cancer Society (IGCS)
1996	American Association for Cancer Research (AACR)
2003	Korean Society of Medical Genetics
2003	Korean Gynecologic Oncology Group (KGOG)
2008	Gynecologic Oncology Group (USA) Ovarian Cancer Committee
2014	President of KGOG

AWARD:

2002.5.3 Korean Society of Gynecologic Oncology Award

2007.4.20. BMS Academic Award

2008.9.26. Korean Society of Obstetrics and Gynecology Award

BIBLIOGRAPHY

Recently published articles among over 240 papers

228. Lee JY, Kim K, Lee TS, Kang S, Seong SJ, Kim JW, Kim BG. Controversies in the management of endometrial cancer: a survey of the Korean Gynecologic Oncology Group. *J Gynecol Oncol*. 2015 Oct;26(4):277-83. doi: 10.3802/jgo.2015.26.4.277. Epub 2015 Sep 23.
229. Song T, Kim MK, Lee YY, Choi CH, Kim TJ, Lee JW, Bae DS, Kim BG. Women with double primary cancers of the colorectum and endometrium: do they have Lynch syndrome? *Eur J Obstet Gynecol Reprod Biol*. 2016 Apr;199:208-12. doi: 10.1016/j.ejogrb.2015.07.018. Epub 2015 Aug 20
230. Paik ES, Lee YY, Shim M, Choi HJ, Kim TJ, Choi CH, Lee JW, Kim BG, Bae DS. Timing and patterns of recurrence in epithelial ovarian cancer patients with no gross residual disease after primary debulking surgery. *Aust N Z J Obstet Gynaecol*. 2016 Sep 9. doi: 10.1111/ajo.12529. [Epub ahead of print]
231. Paik ES, Shim M, Choi HJ, Lee YY, Kim TJ, Lee JW, Kim BG, Bae DS, Choi CH. Impact of lymphadenectomy on survival after recurrence in patients with advanced ovarian cancer without suspected lymph node metastasis. *Gynecol Oncol*. 2016 Aug 23. pii: S0090-8258(16)31347-6. doi: 10.1016/j.ygyno.2016.08.321. [Epub ahead of print]
232. Sugiyama T, Okamoto A, Enomoto T, Hamano T, Aotani E, Terao Y, Suzuki N, Mikami M, Yaegashi N, Kato K, Yoshikawa H, Yokoyama Y, Tanabe H, Nishino K, Nomura H, Kim JW, Kim BG, Pignata S, Alexandre J, Green J, Isonishi S, Terauchi F, Fujiwara K, Aoki D. Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial. *J Clin Oncol*. 2016 Aug 20;34(24):2881-7. doi: 10.1200/JCO.2016.66.9010. Epub 2016 Jul 11.
233. Paik ES, Kim TJ, Lee YY, Choi CH, Lee JW, Kim BG, Bae DS. Comparison of survival outcomes after recurrence detected by cancer antigen 125 elevation versus imaging study in epithelial ovarian cancer. *J Gynecol Oncol*. 2016 Sep;27(5):e46. doi: 10.3802/jgo.2016.27.e46. Epub 2016 May 9
234. Yoon A, Park JJ, Park BK, Lee YY, Paik ES, Choi CH, Kim TJ, Kim CK, Lee JW, Bae DS, Kim BG. Long-term Outcomes of MRI Stage IIB Cervical Cancer. *Int J Gynecol Cancer*. 2016 Sep;26(7):1252-7. doi: 10.1097/IGC.0000000000000762.
235. Kim TH, Kim CJ, Kim TJ, Lee YY, Choi CH, Lee JW, Bae DS, Kim BG. Retroperitoneal Approach in Single-Port Laparoscopic Hysterectomy. *JLS*. 2016 Apr-Jun;20(2). pii: e2016.00001. doi: 10.4293/JLS.2016.00001
236. Choi CH, Chung JY, Kim JH, Kim BG, Hewitt SM. Expression of fibroblast growth factor receptor family members is associated with prognosis in early stage cervical cancer patients. *J Transl Med*. 2016 May 6;14(1):124. doi: 10.1186/s12967-016-0874-0.
237. Choi HJ, Lee S, Park BK, Kim TJ, Kim CK, Park JJ, Choi CH, Lee YY, Lee JW, Bae DS, Kim BG. Long-term outcomes of magnetic resonance imaging-invisible endometrial cancer. *J Gynecol Oncol*. 2016 Jul;27(4):e38. doi: 10.3802/jgo.2016.27.e38. Epub 2016 Apr 18.
238. Paik ES, Lee YY, Kim TJ, Choi CH, Lee JW, Kim BG, Bae DS. Feasibility of laparoscopic cytoreduction in patients with localized recurrent epithelial ovarian cancer. *J Gynecol Oncol*. 2016 May;27(3):e24. doi: 10.3802/jgo.2016.27.e24.

239. Kim TH, Kim HS, Kim TJ, Chang SJ, Kim DY, Ryu SY, Kim BG, Kim YT, Bae DS, Ryu HS, Nam JH. Survival impact based on the thoroughness of pelvic lymphadenectomy in intermediate- or high-risk groups of endometrioid-type endometrial cancer: A multi-center retrospective cohort analysis. *Gynecol Oncol*. 2016 Jun;141(3):440-6. doi: 10.1016/j.ygyno.2016.03.031. Epub 2016 Apr 8.

240. Han HD, Cho YJ, Cho SK, Byeon Y, Jeon HN, Kim HS, Kim BG, Bae DS, Lopez-Berestein G, Sood AK, Shin BC, Park YM, Lee JW. Linalool-Incorporated Nanoparticles as a Novel Anticancer Agent for Epithelial Ovarian Carcinoma. *Mol Cancer Ther*. 2016 Apr;15(4):618-27. doi: 10.1158/1535-7163.MCT-15-0733-T. Epub 2016 Feb 9

241. Park JY, Heo EJ, Lee JW, Lee YY, Kim TJ, Kim BG, Bae DS. Outcomes of laparoscopic fertility-sparing surgery in clinically early-stage epithelial ovarian cancer. *J Gynecol Oncol*. 2016 Mar;27(2):e20. doi: 10.3802/jgo.2016.27.e20.

242. Park B, Park S, Shin HR, Shin A, Yeo Y, Choi JY, Jung KW, Kim BG, Kim YM, Noh DY, Ahn SH, Kim JW, Kang S, Kim JH, Kim TJ, Kang D, Yoo KY, Park SK. Population attributable risks of modifiable reproductive factors for breast and ovarian cancers in Korea. *BMC Cancer*. 2016 Jan 6;16:5. doi: 10.1186/s12885-015-2040-0.

243. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Robert L Coleman, Mark F Brady, Thomas J Herzog, Paul Sabbatini, Deborah K Armstrong, Joan L Walker, Byoung-Gie Kim, Keiichi Fujiwara, Krishnansu S Tewari, David M O'Malley, Susan A Davidson, Stephen C Rubin, Paul DiSilvestro, Karen Basen-Engquist, Helen Huang, John K Chan, Nick M Spirtos, Raheela Ashfaq, Robert S Mannel. *Lancet Oncol* 2017 Published Online April 21, 2017 [http://dx.doi.org/10.1016/S1470-2045\(17\)30279-6](http://dx.doi.org/10.1016/S1470-2045(17)30279-6)